Company code: Wuxi Apptec Co.Ltd(603259) company abbreviation: Wuxi Apptec Co.Ltd(603259) Wuxi Apptec Co.Ltd(603259)
Summary of annual report 2021
Section I important tips
1 the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should http://www.sse.com.cn. The website carefully reads the full text of the annual report. 2. The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 3. All directors of the company attend the board meeting. 4 Deloitte Touche Tohmatsu (special general partnership) has issued a standard unqualified audit report for the company. 5. The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
The company’s profit distribution plan for 2021: Based on the total share capital on the equity registration date of profit distribution in 2021, a cash dividend of RMB 5.1740 (including tax) will be distributed for every 10 shares (based on the current total share capital of the company, a total of RMB 152930614792 (including tax)). If the total share capital of the company changes before the equity registration date of equity distribution, it will be distributed according to the principle that the distribution amount per share remains unchanged, and the total distribution amount will be adjusted accordingly.
Section II basic information of the company
1 company profile
Company stock profile
Stock type stock exchange stock abbreviation stock abbreviation before stock code change
A-share Shanghai Stock Exchange Wuxi Apptec Co.Ltd(603259) Wuxi Apptec Co.Ltd(603259) not applicable
H-share stock exchange Wuxi apptec 02359 is not applicable
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Yao Chi, Fei Xiaqi, Wang Li
Office address: No. 288, Fute Middle Road, tax district, No. 288, Fute Middle Road, Pudong New Area, Shanghai, China
Tel. + 86 (21) 20663091 + 86 (21) 20663091
E-mail [email protected]. [email protected].
2. Introduction to the company’s main business in the reporting period
The company provides new drug R & D and production services for global pharmaceutical, biotechnology and medical device companies. It belongs to the pharmaceutical R & D service industry. The company empowers customers through its own R & D and production platform to help customers carry out new drug R & D faster and better. The company’s main business covers cro, chemical cdmo, cell and gene therapy ctdmo (contract testing, R & D and production) and other fields. At present, most pharmaceutical R & D service companies in the world focus on a certain stage of new drug R & D, such as preclinical cro, clinical trial cro, cdmo, etc. In addition, there are a few “integrated, end-to-end” R & D service platforms, including the company, which can provide customers with one-stop new drug R & D and production services. In the process of “drug discovery and service” from the early stage to the end of the development chain, we can continuously expand the “quality” of drugs, follow the development of new drugs, and provide customers with high-quality services, Achieve sustained growth.
The company is closely related to the development of the global pharmaceutical industry and the investment in new drug research and development. Driven by the vigorous development of the global pharmaceutical industry and the development direction of the industry, the company’s main business has great development opportunities:
First of all, with the development of global economy, the growth of global population, the improvement of population aging, scientific and technological progress, the rise of medical expenditure and the continuous enhancement of public health awareness, it is expected that the scale of global pharmaceutical market will continue to grow.
Secondly, the proportion of outsourcing of large pharmaceutical enterprises has increased, the demand of small and medium-sized pharmaceutical companies is growing, and the global pharmaceutical R & D, production and service industry is expected to maintain rapid growth. On the one hand, innovative drug R & D has the characteristics of high investment, long cycle, high risk and other industries. Under the double squeeze of low R & D return and patent cliff, large pharmaceutical enterprises are expected to promote R & D projects through external R & D service institutions, improve R & D efficiency and reduce R & D costs. On the other hand, small pharmaceutical companies, including small and medium-sized biotechnology companies, virtual companies and individual entrepreneurs, have become an important driving force of pharmaceutical innovation. These small and medium-sized pharmaceutical companies do not have time or sufficient capital to build their own laboratories and production facilities required by their R & D projects, but need to obtain a number of different services required by R & D projects in a short time. Therefore, they will seek outsourcing services for R & D and production, especially “integrated and end-to-end” R & D services, to meet their R & D service needs from concept verification to product listing. According to the Latest Frost & Sullivan report in June 2021, the R & D investment in the global pharmaceutical industry will increase from US $224.1 billion in 2021 to US $312.9 billion in 2026, with a compound annual growth rate of about 6.9%.
In addition, China Meheco Group Co.Ltd(600056) industry has changed from imitation to innovation, and R & D investment is expected to maintain rapid growth. The continuous promotion of a series of policies such as the reform of China’s drug and medical device review and approval system, the listing Licensor system (MAH), generic drug consistency evaluation and volume procurement, and innovative drug health insurance negotiation will drive the continuous growth of China’s innovative drug R & D and production market demand. According to the Frost & Sullivan report, the R & D investment in China Meheco Group Co.Ltd(600056) industry will increase from US $29.8 billion in 2021 to US $55.1 billion in 2026, with a CAGR of about 13.1%.
China Meheco Group Co.Ltd(600056) R & D service industry, especially platform companies with global R & D and production service capacity, is expected to benefit from the rapid growth of R & D investment and outsourcing rate of new drugs in China and around the world. According to the Frost & Sullivan report, the outsourcing proportion of China Meheco Group Co.Ltd(600056) R & D investment will increase from 39.4% in 2021 to 49.9% in 2026, and the outsourcing proportion of global pharmaceutical R & D investment will increase from 43.0% in 2021 to 52.7% in 2026. At the same time, the report predicts that the global outsourcing service market (excluding macromolecular cdmo) provided by China Meheco Group Co.Ltd(600056) R & D service company will increase from 98.5 billion yuan in 2021 to 300.6 billion yuan in 2026, with an average annual increase of about 25%. According to Frost & Sullivan’s latest market research report in June 2021, the market share of the company in China’s drug discovery outsourcing market, China’s preclinical and clinical outsourcing market and China’s small molecule cdmo market ranks first in China, and the market share in the global cell and gene therapy cdmo market ranks fourth in the world.
The company provides integrated and end-to-end new drug R & D and production services for the global biomedical industry, and has operation bases in Asia, Europe, North America and other places. Through the original “crdmo” and “ctdmo” business models, the company continues to reduce the R & D threshold, help customers improve R & D efficiency, and bring more breakthrough treatment solutions to patients. The scope of services covers the R & D and production of chemical drugs, biological research, preclinical and clinical trial research and development, cell and gene therapy research and development, testing and production and other fields.
During the reporting period, the company provided services to more than 5700 active customers from more than 30 countries through 31 operating bases and branches around the world. The company has always adhered to the highest international quality supervision standards. Since its establishment, with its excellent service record and perfect intellectual property protection system, the company has won a recognized excellent reputation in the global pharmaceutical R & D industry. The service data formed by the company has high recognition and credibility in the industry. The company continues to optimize and explore the business synergy between cross platforms, accelerate the pace of globalization, continuously strengthen the company’s unique integrated crdmo (contract research, development and production) and ctdmo (contract detection, research and development and production) business models, and provide real one-stop services to meet the service needs of customers from drug discovery, development to production.
By the end of the reporting period, the company had 34912 employees, including 11001 with master’s degree or above and 1302 with doctor’s degree or equivalent. The breakdown by function and region is as follows:
Asia (people) America (people) Europe (people) Total (people)
R & D 27733962 14628841
Production 3 Weihai Huadong Automation Co.Ltd(002248) 743324
Sales 38 76 32 146
Management and administration 2095433 732601
Total 328681719 32534912
The company will continue to retain outstanding talents through recruitment, training, promotion and incentive, so as to maintain the company’s high-level service and industry-leading professional status and continuously meet the needs of customers.
The company’s main business can be divided into five parts: chemical business, testing business, biological business, cell and gene therapy ctdmo business and China’s new drug R & D service business. The service scope covers the whole process from concept generation to commercial production, and the service areas include China, the United States, Europe and other regions.
3 main accounting data and financial indicators of the company 3.1 main accounting data and financial indicators in recent three years
Unit: yuan currency: RMB
20212020 compared with 2019 of the previous year
Increase or decrease (%)
Total assets 55127388384034629116569855 19.092923913437082
Net assets attributable to listed company shares 38491509630603249374308978 18.461731225540907 East
Operating income 22902385129111653543146541 38.501287220643716
The net profit attributable to listed company shares 509715528368296023549588 72.19185455093458 East belongs to listed company shares
East’s net profit after deducting non recurring profit and loss of 406363317464238510196161 70.38191428326828
Net cash flow from operating activities 458928873311397372822246 15.49291603231270
Weighted average net assets closed at 14.05 and 12.91, an increase of 1.14 percentage points and 10.57 profit rate (%)
Basic earnings per share (yuan / 1.75 1.06 65.09 0.68 shares)
Diluted earnings per share (yuan / 1.73 1.05 64.76 0.67 shares) 3.2 reporting period
